Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416616917> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2416616917 endingPage "38" @default.
- W2416616917 startingPage "2827" @default.
- W2416616917 abstract "Treatment recommendations in chronic lymphocytic leukemia (CLL) are based upon selected, otherwise healthy study populations mostly under 72 years of age. The Project group Internistic Oncology (PIO) embarked on an analysis of the 'real-world' safety and efficacy of bendamustine with and without rituximab in unselected outpatients.A multicenter, open-label, prospectively stratified, retrospective study was conducted to determine routine feasibility, toxicity, and response rates obtained by bendamustine with and without rituximab in a random population of mostly elderly patients with CLL. Records were obtained from 775 patients with CLL from 60 private medical oncology practices. Informed consent was obtained prior to study participation. The median observation time was 28 months. Patients were stratified according to age, and treatment. Response criteria and statistics followed international guidelines adopted by the German Chronic Lymphocytic Leukemia Study Group.Overall, 57.5% of patients were over 70 (range=36-95) years old. Eastern Cooperative Oncology Group performance status and age influenced the total dose given, decreasing by 20% between ECOG 0 and 3, and by 15% above 80 years old. Response rates did not differ between the ages of 60 to 80 years, with an overall remission rate for bendamustine of 83%, and for the combination therapy of 89%, decreasing above the age of 80 years. Febrile neutropenia occurred in 25% of 775 patients, and grade 3 or 4 non-hematological adverse events in 9.55% (n=74), not interfering with the treatment.Bendamustine with and without rituximab was associated with high activity and tolerability, irrespective of age and risk factors. The median overall survival was 64 months with a 3-year survival rate of 72%; progression-free survival was 30.6 months, and the 3 year PFS was 43%. The good tolerability and feasibility of bendamustine with and without rituximab, in particular for the elderly population with CLL argues for it being a safe outpatient treatment." @default.
- W2416616917 created "2016-06-24" @default.
- W2416616917 creator A5029295788 @default.
- W2416616917 creator A5034836935 @default.
- W2416616917 creator A5054366345 @default.
- W2416616917 creator A5061839608 @default.
- W2416616917 creator A5078417193 @default.
- W2416616917 date "2016-06-01" @default.
- W2416616917 modified "2023-10-03" @default.
- W2416616917 title "Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature." @default.
- W2416616917 cites W154103547 @default.
- W2416616917 cites W1565211228 @default.
- W2416616917 cites W1783223960 @default.
- W2416616917 cites W1965851569 @default.
- W2416616917 cites W1993986769 @default.
- W2416616917 cites W2018946689 @default.
- W2416616917 cites W2028530851 @default.
- W2416616917 cites W2040501000 @default.
- W2416616917 cites W2060520350 @default.
- W2416616917 cites W2063513615 @default.
- W2416616917 cites W2097018150 @default.
- W2416616917 cites W2112998032 @default.
- W2416616917 cites W2115637430 @default.
- W2416616917 cites W2116385028 @default.
- W2416616917 cites W2128936398 @default.
- W2416616917 cites W2131998596 @default.
- W2416616917 cites W2144617723 @default.
- W2416616917 cites W2752308580 @default.
- W2416616917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27272794" @default.
- W2416616917 hasPublicationYear "2016" @default.
- W2416616917 type Work @default.
- W2416616917 sameAs 2416616917 @default.
- W2416616917 citedByCount "1" @default.
- W2416616917 countsByYear W24166169172018 @default.
- W2416616917 crossrefType "journal-article" @default.
- W2416616917 hasAuthorship W2416616917A5029295788 @default.
- W2416616917 hasAuthorship W2416616917A5034836935 @default.
- W2416616917 hasAuthorship W2416616917A5054366345 @default.
- W2416616917 hasAuthorship W2416616917A5061839608 @default.
- W2416616917 hasAuthorship W2416616917A5078417193 @default.
- W2416616917 hasConcept C126322002 @default.
- W2416616917 hasConcept C141071460 @default.
- W2416616917 hasConcept C187212893 @default.
- W2416616917 hasConcept C197934379 @default.
- W2416616917 hasConcept C2776694085 @default.
- W2416616917 hasConcept C2777063308 @default.
- W2416616917 hasConcept C2777938653 @default.
- W2416616917 hasConcept C2778375690 @default.
- W2416616917 hasConcept C2778461978 @default.
- W2416616917 hasConcept C2779338263 @default.
- W2416616917 hasConcept C2780653079 @default.
- W2416616917 hasConcept C2781442060 @default.
- W2416616917 hasConcept C2908647359 @default.
- W2416616917 hasConcept C71924100 @default.
- W2416616917 hasConcept C99454951 @default.
- W2416616917 hasConceptScore W2416616917C126322002 @default.
- W2416616917 hasConceptScore W2416616917C141071460 @default.
- W2416616917 hasConceptScore W2416616917C187212893 @default.
- W2416616917 hasConceptScore W2416616917C197934379 @default.
- W2416616917 hasConceptScore W2416616917C2776694085 @default.
- W2416616917 hasConceptScore W2416616917C2777063308 @default.
- W2416616917 hasConceptScore W2416616917C2777938653 @default.
- W2416616917 hasConceptScore W2416616917C2778375690 @default.
- W2416616917 hasConceptScore W2416616917C2778461978 @default.
- W2416616917 hasConceptScore W2416616917C2779338263 @default.
- W2416616917 hasConceptScore W2416616917C2780653079 @default.
- W2416616917 hasConceptScore W2416616917C2781442060 @default.
- W2416616917 hasConceptScore W2416616917C2908647359 @default.
- W2416616917 hasConceptScore W2416616917C71924100 @default.
- W2416616917 hasConceptScore W2416616917C99454951 @default.
- W2416616917 hasIssue "6" @default.
- W2416616917 hasLocation W24166169171 @default.
- W2416616917 hasOpenAccess W2416616917 @default.
- W2416616917 hasPrimaryLocation W24166169171 @default.
- W2416616917 hasRelatedWork W1696810722 @default.
- W2416616917 hasRelatedWork W1984111648 @default.
- W2416616917 hasRelatedWork W2012302440 @default.
- W2416616917 hasRelatedWork W2116137820 @default.
- W2416616917 hasRelatedWork W2142682900 @default.
- W2416616917 hasRelatedWork W2416616917 @default.
- W2416616917 hasRelatedWork W2558160214 @default.
- W2416616917 hasRelatedWork W2790101833 @default.
- W2416616917 hasRelatedWork W2984690643 @default.
- W2416616917 hasRelatedWork W3134524629 @default.
- W2416616917 hasVolume "36" @default.
- W2416616917 isParatext "false" @default.
- W2416616917 isRetracted "false" @default.
- W2416616917 magId "2416616917" @default.
- W2416616917 workType "article" @default.